Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228481 | 1.00 | ADK (0.40) | ADKPRMT5WDR77DNMT1DNMT3B | |
| SCHEMBL3238152 | 0.85 | PRMT5 (0.41) | ADKPRMT5WDR77DNMT1DNMT3B | |
| Salicylic Acid SCHEMBL3238127 | 0.84 | PRMT5 (0.42) | ADKPRMT5WDR77DNMT1DNMT3B | |
| SCHEMBL3229893 | 0.77 | PRMT5 (0.50) | ADKPRMT5WDR77ADORA2A | |
| SCHEMBL21006387 | 0.77 | PRMT5 (0.50) | ADKPRMT5WDR77ADORA2A | |
| SCHEMBL19537076 | 0.77 | PRMT5 (0.50) | ADKPRMT5WDR77ADORA2A | |
| SCHEMBL17109566 | 0.77 | PRMT5 (0.50) | ADKPRMT5WDR77ADORA2A | |
| SCHEMBL3234238 | 0.77 | PRMT5 (0.50) | ADKPRMT5WDR77ADORA2A | |
| SCHEMBL19535607 | 0.77 | PRMT5 (0.50) | ADKPRMT5WDR77ADORA2A | |
| SCHEMBL1736124 | 0.77 | PRMT5 (0.50) | ADKPRMT5WDR77ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | claimed |
| WO-2010015643-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | claimed |
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| WO-2010015643-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144655-A1 | ORGANIC COMPOUNDS | OAT, MAVS, HAVCR2 | ADK 3634/4885PRMT5 1914/4885WDR77 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.